What Senti Biosciences does

Senti Biosciences is a clinical-stage biotechnology company founded in 2016 by synthetic biology pioneer Tim Lu, headquartered in South San Francisco and publicly traded on Nasdaq under the ticker SNTI following a June 2022 business combination with Dynamics Special Purpose Corp. The company develops next-generation cell and gene therapies for cancer using its proprietary Gene Circuit Technology Platform, which programs cells (both NK and T cells) with biological logic to sense disease inputs, compute decisions, and selectively respond. Core platform components include Logic Gating (Boolean OR/NOT gates), Multi-Arming (multi-pathway targeting within a single allogeneic product), Regulator Dial (small-molecule-controlled expression), Smart Sensor (microenvironment-responsive activation), and Calibrated-Release IL-15 (engineered cytokine release for cell persistence).

Senti Bio's lead product candidate, SENTI-202, is a first-in-class off-the-shelf Logic-Gated CAR-NK cell therapy featuring an OR-gate CAR targeting CD33 and/or FLT3, a NOT-gate CAR protecting healthy bone marrow cells expressing EMCN, and calibrated-release IL-15. It is being evaluated in a global Phase 1 trial (NCT06325748) at multiple sites in the United States and Australia for adults with relapsed/refractory acute myeloid leukemia (AML), with potential expansion into myelodysplastic syndrome (MDS) and pediatric AML. Phase 1 data reported a 50% composite complete remission rate in Donor X-derived NK cells versus 12.5% in non-Donor X, and 42% CR at the recommended Phase 2 dose, with all CR patients MRD-negative and remissions extending beyond 21 months. SENTI-202 received FDA Orphan Drug Designation in June 2025 and FDA Regenerative Medicine Advanced Therapy (RMAT) designation in December 2025. The pipeline also includes an undisclosed solid tumor gene-circuit CAR program in discovery.

The company is pre-revenue, with Q4 2025 reported revenue of approximately $22,000 and FY 2025 net loss of $61.4 million. The intended revenue model is one-time product sales of off-the-shelf allogeneic cell therapies upon regulatory approval, supplemented in the interim by capital markets financings (SPAC merger, PIPE, convertible notes) and non-dilutive grants (notably an $8 million CIRM grant plus a $1 million milestone tranche). Patients currently access SENTI-202 exclusively through company-sponsored clinical trials; commercialization is planned on an off-the-shelf basis with traditional pharmaceutical distribution. Key recent financing includes a $50.6 million PIPE in December 2024 and a $40 million senior secured convertible note facility from Celadon Partners SPV 24 (with up to $60 million in CVRs) signed in April 2026, alongside a holding company reorganization in April 2026 creating Senti Biosciences Holdings, Inc.

Name

Senti Biosciences

Legal name

Senti Biosciences, Inc.

Website

https://www.sentibio.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Senti Biosciences is a clinical-stage biotech developing off-the-shelf CAR-NK and CAR-T cell therapies engineered with proprietary Gene Circuits for cancer, with lead candidate SENTI-202 in a global Phase 1 trial for relapsed/refractory AML.

Ownership category

akta.pro rank

Product category

Cancer Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

NK Cell Therapies (HLAAABAD)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Cell and gene therapy
• Car-nk cell therapy
• Synthetic biology platform
• Gene circuit technology
• Cancer immunotherapy

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Cell and Gene Therapy Development / Future Commercialization: As a clinical-stage biotechnology company, Senti Biosciences currently has no revenue. The company is developing cell therapies engineered with Gene Circuits targeting liquid and solid tumors. If SENTI-202 or other pipeline candidates receive regulatory approval, the company would generate revenue from product sales of off-the-shelf CAR-NK cell therapies.
2. Strategic Financing and Grants: The company raises capital through public market financings, convertible note facilities, grants (CIRM), and business combinations to fund R&D operations. Revenue from therapeutic commercialization is the intended long-term revenue stream.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Senti Biosciences develops gene circuit-enhanced cell and gene therapies for cancer, with its lead candidate SENTI-202 being a first-in-class off-the-shelf Logic-Gated CAR-NK cell therapy for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. The company's wholly-owned pipeline is built on a proprietary Gene Circuit Technology Platform that programs therapeutic cells with biological logic (OR/NOT gates, multi-arming, regulator dial, smart sensor modules) to selectively kill cancer cells while sparing healthy tissue, validated in both NK and T cells.

Product overview

Senti Biosciences is a clinical-stage biotechnology company with a proprietary Gene Circuit Technology Platform for developing next-generation cell and gene therapies. The company's wholly-owned pipeline centers on SENTI-202, a first-in-class off-the-shelf Logic-Gated CAR-NK cell therapy for acute myeloid leukemia and myelodysplastic syndrome, which incorporates OR GATE and NOT GATE gene circuits for precise cancer cell targeting while sparing healthy cells. The platform also includes discovery-stage programs for solid tumors. Gene Circuits can be applied to both NK and T cells, allowing optimal cell type selection for each indication.

Differentiator

Problem solved

Functional benefit

Products and services

• SENTI-202 First-in-class off-the-shelf Logic-Gated selective CD33 OR FLT3 NOT EMCN CAR-NK cell therapy for the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Combines an OR GATE CAR targeting CD33 and/or FLT3, a NOT GATE CAR protecting healthy cells expressing EMCN, and calibrated-release IL-15 for enhanced NK cell persistence and activity. Investigational; accessed via Phase 1 clinical trial enrollment.
• Gene Circuit Technology Platform Proprietary synthetic biology platform that programs next-generation cell and gene therapies by engineering Gene Circuits into therapeutic cells, enabling precision targeting of diseased cells while sparing healthy cells. Incorporates Logic Gating, Multi-Arming, Regulator Dial, and Smart Sensor modules. Validated clinically and preclinically in both NK and T cells. Underpins Senti's pipeline and is available for indication selection across oncology and other disease areas.
• Undisclosed Solid Tumor Program Discovery-stage gene circuit-enhanced CAR cell therapy program targeting solid tumors. Investigational; not yet in clinical trials.

Quantifiable outcome

• 50% composite complete remission rate in patients receiving Donor X-derived NK cells vs. 12.5% for non-Donor X
• +4 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Clinical Trial Sites (US and Australia)coreOthersSENTI-202 Phase 1 clinical trial is being conducted at multiple clinical sites across the United States and Australia. Principal investigators include those from Sarah Cannon Research Institute, MD Anderson Cancer Center, and other leading hematology/oncology research institutions.
• Healthy Adult Donors for NK Cell SourcingcoreOthersSENTI-202 is manufactured using peripheral blood NK cells from selected healthy adult donors. The company has established donor selection criteria, identifying a 'Donor X' phenotype that correlates with significantly improved efficacy (50% CR rate vs. 12.5%). Donor-derived NK cells enable scalable off-the-shelf manufacturing.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Fate Therapeutics: Develops off-the-shelf iPSC-derived NK and T-cell therapies for cancer. Closely comparable allogeneic platform with a similar focus on scalable, multiplexed engineered cell therapies in heme and solid tumors.
• Adicet Bio: Clinical-stage biotech developing allogeneic gamma-delta CAR-T and CAR-NK cell therapies for cancer. Comparable off-the-shelf cell therapy format with overlapping heme and solid tumor indications.
• Caribou Biosciences: Clinical-stage allogeneic CAR-T and NK cell therapy developer using CRISPR-based genome editing. Comparable gene-edited, off-the-shelf cell therapy approach with shared regulatory pathway and indication overlap.
• Century Therapeutics: Develops iPSC-derived allogeneic cell therapies (NK and T cells) engineered with multiple modalities including gene editing. Highly comparable platform model targeting hematologic malignancies and solid tumors.
• Allogene Therapeutics: Pioneer in allogeneic CAR-T cell therapies for hematologic cancers. Comparable off-the-shelf cell therapy model targeting similar oncology patient populations and clinical-stage regulatory milestones.
• Nkarta Therapeutics: Clinical-stage biotech developing allogeneic CAR-NK cell therapies for hematologic malignancies and solid tumors. Most direct competitor to Senti's CAR-NK approach, including overlapping NK cell engineering and oncology indications.
• Cellectis: Clinical-stage gene-edited allogeneic CAR-T cell therapy developer using TALEN-based editing. Operates in the same allogeneic engineered cell therapy space with similar platform-level differentiation.

Broad incumbents

• CRISPR Therapeutics: Leading gene-editing company developing Cas9-based ex vivo cell therapies including allogeneic CAR-T programs. Compares as a broader, well-capitalized incumbent with overlapping gene-editing cell therapy capabilities.

Emerging players

• Beam Therapeutics: Develops base-editing and ex vivo cell therapies, including gene-edited CAR-T programs. Comparable as a programmable gene-editing platform applied to engineered cell therapies, though differentiated by editing chemistry.

Regional players

• Precigen: Clinical-stage gene and cell therapy company with a focus on ultra-rare and oncology indications, including CAR-T programs. Comparable as an engineered cell therapy developer, but with a distinct regulatory and manufacturing platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/sentibio
• LinkedInlinkedin.com/company/senti-biosciences

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds13 records

Investors39 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Senti Biosciences